Lantheus Holdings Inc (LNTH)

NASDAQ
86.81
-2.87(-3.20%)
After Hours
87.34
+0.53(+0.61%)
- Real-time Data
  • Volume:
    1,309,358
  • Day's Range:
    83.60 - 90.97
  • 52 wk Range:
    47.46 - 100.85

LNTH Overview

Prev. Close
89.68
Day's Range
83.6-90.97
Revenue
1.03B
Open
90.23
52 wk Range
47.46-100.85
EPS
-0.259
Volume
1,309,358
Market Cap
5.93B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,015,516
P/E Ratio
-343.86
Beta
0.657
1-Year Change
19.49%
Shares Outstanding
68,332,890
Next Earnings Date
Jul 26, 2023
What is your sentiment on Lantheus Holdings Inc?
or
Market is currently closed. Voting is open during market hours.

Lantheus Holdings Inc Company Profile

Lantheus Holdings Inc Company Profile

Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company's products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company's license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.

Read More

Analyst Price Target

Average123.57 (+42.35% Upside)
High130.00
Low113.00
Price86.81
No. of Analysts7
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellSellStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • Did somebody already receive a payment of the Contingent Value Right related to the merger with PGNX. First payment date should have been 12/31/2022, but impossible to receive any information
    0
    • buy now !! new price target
      0
      • thank you so much for the info
        0
    • +1 FDA agreement.
      0
      • Association with PGNX could lead to significant progress.
        0